Related Experiment Video
Updated: Jun 17, 2026
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
[Thymolipoma associated with myasthenia gravis]
T Taniguchi1, N Usami, N Oohata
1Division of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kyobu Geka. the Japanese Journal of Thoracic Surgery
|December 17, 2009
Summary
This case report details a large thymolipoma, a rare tumor of the thymus gland, associated with myasthenia gravis in a 42-year-old woman. Surgical removal of the thymolipoma led to symptom improvement.
Area of Science:
- Neurology
- Thoracic Surgery
- Pathology
Background:
- Myasthenia gravis is an autoimmune disorder affecting neuromuscular junctions.
- Anterior mediastinal masses, including thymolipoma, can be associated with myasthenia gravis.
- Thymolipoma is a rare, benign tumor of the thymus composed primarily of mature adipose tissue.
Observation:
- A 42-year-old woman presented with ptosis, diplopia, and muscle weakness, diagnosed as myasthenia gravis.
- Imaging revealed a large anterior mediastinal mass, suspected to be thymolipoma.
- A 1,500-gram thymolipoma was surgically removed via median sternotomy.
Findings:
- Histopathology confirmed a typical thymolipoma with mature adipose tissue and thymic elements.
- The thymic tissue lacked germinal centers, a characteristic finding in some thymolipomas.
- This represents the 24th reported association of thymolipoma with myasthenia gravis.
Implications:
- Surgical resection of thymolipoma may be a crucial treatment for associated myasthenia gravis.
- This case highlights the importance of investigating mediastinal masses in patients with myasthenia gravis.
- Further research is needed to understand the specific relationship between thymolipoma and myasthenia gravis pathogenesis.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...